Adverse effects cast doubt over Sanofi's Taxotere follow on Jevtana, says NICE
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued draft guidance declining to recommend Sanofi-Aventis' Jevtana (cabazitaxel) for some prostate cancer patients already treated with the docetaxel (Sanofi's Taxotere). The drug's high cost and concerns about adverse events led the institute to conclude that the drug would not be cost-effective.